Health Affairs January 22, 2025
E. Albert Reece, Jeffrey R. Balser, Kirsten Bibbins-Domingo, Claire M. Fraser, Linda P. Fried, Ann Kurth, Sudip Parikh, Randall L. Rutta, Mary Woolley, Keith R. Yamamoto, Elias Zerhouni, Huda Y. Zoghbi, Victor J. Dzau

Abstract

The US biomedical research enterprise is renowned for its historical and ongoing scientific breakthroughs and advancements. Yet its capacity to solve complex health issues, bridge health equity gaps, and strengthen public trust is constrained by the lack of an overarching national vision, fragmented coordination for research funding, and critical workforce recruitment and retention challenges. To improve national health outcomes and retain global competitiveness, the sector must embrace new approaches. This article, part of the National Academy of Medicine’s Vital Directions for Health and Health Care: Priorities for 2025 initiative, identifies four key opportunities to revitalize the biomedical research enterprise: establishing a national advisory body, bolstering the workforce, prioritizing research to reduce health disparities, and developing approaches to streamlining and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Pharma / Biotech
The next 15 drugs for Medicare price negotiations
Medicare Negotiations Could Fuel, Not Stifle, Innovation
Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says
Google DeepMind CEO: AI-Designed Drugs Coming to Clinical Trials in 2025
Moderna gets $590M from US government for bird flu vaccine

Share This Article